EUVIMEDEUVIMED entdecken
Crossref

Ultralow Dose Rituximab Combined With IVIG Is Safe and Effective in Pemphigus Vulgaris: Single‐Center Review of 24 Patients

Andrew Awad iD, Jessica McClatchy iD, Ann Ramirez, Tami Yap, Laura Scardamaglia iD

Australasian Journal of Dermatology · 2025

DOI: 10.1111/ajd.70003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Australasian Journal of Dermatology, 2025. Verfasst von Andrew Awad und 4 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Department, The Royal Melbourne Hospital, Melbourne, Australia. Hauptthemen laut MEDLINE: Pemphigus, Rituximab, Immunoglobulins, Intravenous, Immunologic Factors. Die Arbeit nennt 11 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We present a combined ultralow dose rituximab and intravenous immunoglobulin protocol for the treatment of moderate to severe pemphigus vulgaris which has been proven to be safe and effective in a series of 24 rituximab naïve patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PemphigusRituximabImmunoglobulins, IntravenousImmunologic FactorsHumansFemaleMaleMiddle AgedAdultAgedDrug Therapy, CombinationRetrospective StudiesTreatment Outcome

Stichwörter der Autor:innen

IVIGanti‐CD20low dosepemphigus vulgarisrituximab

Substanzen

RituximabImmunoglobulins, IntravenousImmunologic Factors

Autor:innen und Institutionen

  • Dermatology Department, The Royal Melbourne Hospital, Melbourne, Australia.
  • College of Medicine and Public Health, Flinders University, South Australia, Australia.
  • Faculty of Medicine Dentistry and Health Sciences, The University of Melbourne, Melbourne, Australia.
  • Melbourne Dental School, The University of Melbourne, Melbourne, Australia.
  • Dermatology Department, Western Health, Melbourne, Australia.
  • Dermatology Department, The Royal Children's Hospital, Melbourne, Australia.

ORCID-Profile: Andrew Awad, Jessica McClatchy, Laura Scardamaglia

Zitieren

APA

Awad, A., McClatchy, J., Ramirez, A., Yap, T., & Scardamaglia, L. (2025). Ultralow Dose Rituximab Combined With IVIG Is Safe and Effective in Pemphigus Vulgaris: Single‐Center Review of 24 Patients. Australasian Journal of Dermatology. https://doi.org/10.1111/ajd.70003

Vancouver

Awad A, McClatchy J, Ramirez A, Yap T, Scardamaglia L. Ultralow Dose Rituximab Combined With IVIG Is Safe and Effective in Pemphigus Vulgaris: Single‐Center Review of 24 Patients. Australasian Journal of Dermatology. 2025. doi:10.1111/ajd.70003

BibTeX
@article{Awad2025,
  author = {Awad, Andrew and McClatchy, Jessica and Ramirez, Ann and Yap, Tami and Scardamaglia, Laura},
  title = {Ultralow Dose Rituximab Combined With IVIG Is Safe and Effective in Pemphigus Vulgaris: Single‐Center Review of 24 Patients},
  journal = {Australasian Journal of Dermatology},
  year = {2025},
  doi = {10.1111/ajd.70003}
}
Kostenlos starten →